2023 World Conference on Lung Cancer (Posters)-EP11.01. SPD-CD40L Prevents Tumor Growth via Recruitment of Immune Cells to the Tumor Microenvironment

EP11.01. SPD-CD40L Prevents Tumor Growth via Recruitment of Immune Cells to the Tumor Microenvironment - PDF(Abstract)

Pdf Summary

The study presented at WCLC 2023 investigated the use of SPD-CD40L, a chimeric gene, to prevent tumor growth in metastatic non-small cell lung cancer. The researchers hypothesized that activating dendritic cells (DCs) in the tumor microenvironment (TME) would lead to the production of anti-tumor T cell responses. <br /><br />To test their hypothesis, the researchers injected the SPD-CD40L gene into B16 melanoma cells in mice and observed the effect on immune cell recruitment to the TME and tumor cell proliferation. They found that SPD-CD40L activated DCs similar to LPS, a known DC activator. Moreover, the injection of the SPD-CD40L gene into B16 tumors inhibited tumor cell growth. Expression of SPD-CD40L by the tumor cells also led to the recruitment of immune cells to the TME. <br /><br />Based on these findings, the researchers concluded that SPD-CD40L can inhibit tumor proliferation, recruit immune cells to the TME, and activate DCs. They suggest that future studies should identify the specific immune cells recruited and investigate the potential synergistic effect of using SPD-CD40L and immune checkpoint inhibitors (ICI) in improving the anti-tumor response.<br /><br />Overall, this study highlights the importance of the TME in the response to immunotherapy in metastatic non-small cell lung cancer and the potential of SPD-CD40L as a therapeutic strategy to enhance the anti-tumor immune response.

Asset Subtitle

Gregory Holt

Meta Tag

Speaker Gregory Holt

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

WCLC 2023

SPD-CD40L

chimeric gene

metastatic non-small cell lung cancer

dendritic cells

tumor microenvironment

anti-tumor T cell responses

B16 melanoma cells

immune cell recruitment

tumor cell proliferation